Your browser is no longer supported. Please, upgrade your browser.
Settings
ARNA Arena Pharmaceuticals, Inc. daily Stock Chart
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own0.60% Shs Outstand242.25M Perf Week-0.74%
Market Cap654.08M Forward P/E- EPS next Y-0.54 Insider Trans-9.14% Shs Float240.81M Perf Month-33.33%
Income-93.80M PEG- EPS next Q-0.14 Inst Own58.50% Short Float11.77% Perf Quarter-36.77%
Sales38.80M P/S16.86 EPS this Y-211.10% Inst Trans0.20% Short Ratio10.44 Perf Half Y-36.17%
Book/sh0.44 P/B6.14 EPS next Y-8.00% ROA-29.70% Target Price7.38 Perf Year-34.47%
Cash/sh0.89 P/C3.02 EPS next 5Y- ROE-104.40% 52W Range2.54 - 6.28 Perf YTD-22.19%
Dividend- P/FCF- EPS past 5Y31.20% ROI-89.20% 52W High-56.05% Beta-2.03
Dividend %- Quick Ratio3.60 Sales past 5Y28.90% Gross Margin71.40% 52W Low8.66% ATR0.20
Employees325 Current Ratio3.80 Sales Q/Q-28.10% Oper. Margin- RSI (14)34.68 Volatility6.35% 6.91%
OptionableYes Debt/Eq0.65 EPS Q/Q-466.70% Profit Margin- Rel Volume0.93 Prev Close2.70
ShortableYes LT Debt/Eq0.62 EarningsAug 05 AMC Payout- Avg Volume2.71M Price2.76
Recom2.70 SMA20-9.80% SMA50-27.39% SMA200-34.90% Volume1,335,713 Change2.22%
May-12-15Reiterated WallachBeth Buy $8 → $6
Jan-23-15Initiated RBC Capital Mkts Sector Perform $5
Aug-07-14Reiterated WallachBeth Buy $9 → $8
Nov-15-13Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Market Perform $4.50
Oct-25-10Reiterated Barclays Capital Underweight $3 → $2
Sep-20-10Reiterated UBS Neutral $7 → $2
Sep-17-10Downgrade Davenport Buy → Neutral
Sep-14-10Downgrade Barclays Capital Equal Weight → Underweight $4 → $3
Aug-23-10Reiterated UBS Neutral $3.50 → $7
Jul-16-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1
Jul-02-10Reiterated UBS Buy $40 → $38
Feb-04-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
Dec-17-09Initiated Jefferies & Co Hold $4
Sep-21-09Downgrade Leerink Swann Outperform → Mkt Perform $6
Sep-18-09Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $3
Sep-15-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Aug-18-09Initiated JMP Securities Mkt Perform
Jun-24-09Initiated Rodman & Renshaw Mkt Outperform $9
Mar-16-09Downgrade Canaccord Adams Hold → Sell
Sep-03-15 08:00AM  Arena Pharmaceuticals to Present at the Wells Fargo 2015 Healthcare Conference PR Newswire
Aug-31-15 05:56PM  Westaim completes Arena Transactions CNW Group
Aug-28-15 05:15PM  3 Battleground Biotech Stocks I Would Avoid at All Costs at Motley Fool
Aug-27-15 09:02AM  Arena's Cloud PLM Integrates With Kenandy's Cloud ERP CNW Group
Aug-24-15 08:44AM  Arena Pharmaceuticals (ARNA) Rises: Stock Adds 5.7% in Session -8.59%
Aug-23-15 02:37PM  Bull Or Bear? Biotech's Post-Earnings Buys and Sells at Motley Fool
10:57AM  The 3 Most Disappointing Drug Launches of All Time at Motley Fool
Aug-20-15 01:04PM  ARENA PHARMACEUTICALS INC Financials -6.95%
Aug-18-15 09:02AM  Arena Solutions Partners with GoodData to Create Arena Analytics CNW Group -6.12%
Aug-12-15 10:40AM  Arena Pharmaceuticals' Belviq Sales Are Better Than They Appear (But They're Still Not Great) at Motley Fool
Aug-11-15 09:02AM  Medical Device Companies Embrace Arena's Cloud-Based PLM Solution CNW Group
Aug-09-15 08:13PM  10-Q for Arena Pharmaceuticals, Inc. at Company Spotlight
Aug-07-15 06:10AM  Biotech Stock Mailbag: Controversial Stocks Revisited at TheStreet
Aug-06-15 05:35PM  Arena Pharmaceuticals Slims Down After Its Q2 Report at Motley Fool -8.44%
09:10AM  Arena Pharmaceuticals 2Q Loss Narrower-Than-Expected - Analyst Blog
Aug-05-15 09:37PM  Edited Transcript of ARNA earnings conference call or presentation 5-Aug-15 9:00pm GMT
07:01PM  Arena Pharmaceuticals reports 2Q loss
05:00PM  Arena Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today
04:19PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  Arena Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update PR Newswire
07:07AM  Q2 2015 Arena Pharmaceuticals Inc Earnings Release - After Market Close
Aug-04-15 01:00PM  Will Arena Pharmaceuticals (ARNA) Surprise Q2 Earnings? - Analyst Blog
09:02AM  EMA Adds Industry First Bi-directional Interface Between OrCAD and Arena PLM CNW Group
08:53AM  Is a Surprise Coming for Arena Pharmaceuticals (ARNA) This Earnings Season? - Tale of the Tape
Jul-30-15 08:00AM  Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 PR Newswire
Jul-29-15 08:00AM  Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 Receptor Modulator for Autoimmune Diseases PR Newswire
Jul-23-15 09:01AM  Arena Solutions Grows New Enterprise Customer Count 75 Percent in Q2 2015 over Same Period in 2014 CNW Group
Jul-21-15 04:27PM  Celgene Buys Receptos. Is Arena Pharmaceuticals Next? at Motley Fool
Jul-20-15 08:29AM  Westaim provides update on status of Arena transactions CNW Group
Jul-15-15 01:56PM  3 Biotech Stocks to Trade Off the Receptos Buyout at TheStreet +6.49%
12:39PM  Wednesday's Mid-Day Movers: Does The U.S. Benefit From Iran Deal?; Celgene-Receptos And More
11:12AM  Celgene Hits High As Street Applauds Receptos Buyout at Investor's Business Daily
Jul-09-15 05:22PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jul-05-15 02:18PM  Obesity Statistics Take a Wrong Turn in This Latest Study at Motley Fool
Jun-17-15 09:57AM  Arena Pharmaceuticals (ARNA) Stock Declines on CFO Departure at TheStreet
Jun-16-15 05:52PM  Sportsman's Warehouse, Bob Evans, Peabody Energy Lead Tuesday's After-Hours Movers
05:47PM  After-hours buzz: DavidsTea, La-Z-Boy, Adobe & more at CNBC
04:57PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a V
04:30PM  Arena Pharmaceuticals Announces the Departure of Chief Financial Officer PR Newswire
Jun-11-15 09:00AM  Arena Solutions and SunPower to Speak At CIMdata's High Tech PLM Conference CNW Group
Jun-04-15 01:30PM  Lorcaserin HCl Data to be Presented at American Diabetes Association's 75th Scientific Sessions PR Newswire
May-26-15 08:00AM  Arena Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference PR Newswire
May-14-15 08:00AM  Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at Upcoming Medical Meetings PR Newswire
12:22AM  5 Key Takeaways Following Arena's Q1 Results at Investopedia
May-13-15 08:11PM  10-Q for Arena Pharmaceuticals, Inc. at Company Spotlight
11:35AM  5 New Biotech Developments Worth Watching
May-12-15 09:10AM  Arena Pharmaceuticals 1Q Loss Narrower-Than-Expected - Analyst Blog
May-11-15 07:48PM  Arena Pharmaceuticals reports 1Q loss
05:00PM  Arena Pharmaceuticals Inc Earnings call Call scheduled for 5:00 pm ET today
04:22PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:07PM  Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2015 Financial Results PR Newswire
04:01PM  Arena Pharmaceuticals and Roivant Sciences Enter into Collaboration for Nelotanserin, a Novel Inverse Agonist of the 5-HT2A Receptor PR Newswire
07:07AM  Q1 2015 Arena Pharmaceuticals Inc Earnings Release - After Market Close
May-08-15 08:00AM  Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference PR Newswire
May-07-15 04:00PM  Will Arena Pharmaceuticals (ARNA) Surprise this Earnings? - Analyst Blog
03:03PM  3 Things Arena's Management Wants You to Know at Investopedia
08:27AM  Arena Pharmaceuticals to Host First Quarter 2015 Financial Results Conference Call and Webcast on Monday, May 11 at noodls
08:00AM  Arena Pharmaceuticals to Host First Quarter 2015 Financial Results Conference Call and Webcast on Monday, May 11 PR Newswire
May-06-15 07:07AM  Q1 2015 Arena Pharmaceuticals Inc Earnings Release - After Market Close
May-05-15 05:13PM  The Westaim Corporation Announces $200 Million Bought Deal Private Placement and Concurrent Private Placement of Special Warrants to Pursue New Business Lines at noodls
Apr-30-15 01:11PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Apr-29-15 08:31AM  Arena Pharmaceuticals Reports Favorable Results from Phase 1 Single-Ascending Dose Clinical Trial of APD371 at noodls
08:00AM  Arena Pharmaceuticals Reports Favorable Results from Phase 1 Single-Ascending Dose Clinical Trial of APD371 PR Newswire
Apr-28-15 01:33PM  5 Biotech Stocks to Avoid After Monday's Slump - Analyst Blog
09:05AM  Arena Adds Most New Customers in Company History to Close Record Quarter CNW Group
Apr-27-15 06:58PM  Arena Solutions and Q Point Technology Partner to Offer Arena PLM with Q Point's Online Green Data Exchange CNW Group -6.01%
Apr-23-15 06:37PM  Orexigen's Obesity Drug Contrave Faces Generic Threat - Analyst Blog
08:09AM  Eisai and Arena Pharmaceuticals Complete Registrational Trials of an Extended Release Formulation of Lorcaserin at noodls
Apr-21-15 09:30AM  Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Apr-13-15 05:09PM  Arena, Eisai Finish Phase I Studies on Obesity Drug Belviq - Analyst Blog
Apr-10-15 08:31AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
08:00AM  Eisai and Arena Pharmaceuticals Complete Registrational Trials of an Extended Release Formulation of Lorcaserin PR Newswire
02:00AM  Eisai Drops On US Job Cuts, Still A Stunning Run On Alzheimer's Drug With Biogen at Barrons.com
Apr-09-15 08:12AM  Arena Pharmaceuticals to Present at the Annual Needham Healthcare Conference at noodls
08:00AM  Arena Pharmaceuticals to Present at the Annual Needham Healthcare Conference PR Newswire
Apr-08-15 10:00AM  Arena Pharmaceuticals Up on Belviq's New Patent Approval - Analyst Blog
08:14AM  Calls look to ride Arena Pharma
Apr-07-15 11:34AM  Arena Pharmaceuticals (ARNA) Stock Gains Today on New Patent Approval at TheStreet
10:52AM  Arena Pharmaceuticals shares rise on weight loss drug patent
08:17AM  Arena Pharmaceuticals Receives Additional Patent for BELVIQ® (lorcaserin HCl) from United States Patent and Trademark Office at noodls
08:00AM  Arena Pharmaceuticals Receives Additional Patent for BELVIQ® (lorcaserin HCl) from United States Patent and Trademark Office PR Newswire
Apr-02-15 08:26PM  3 Ways Arena Can Boost Shareholder Value at Investopedia
02:40PM  Vivus Goes on a Diet: Sales Reps are Cut, but Will FDA Help Save Money? at The Wall Street Journal
01:47PM  Sports & Entertainment Group Announces Strategic Partnership with AEG Facilities for Québec City Arena at noodls
Mar-27-15 08:25AM  Ahead of the Bell: Orexigen shares rise
Mar-19-15 09:30AM  Zacks Rank #5 Additions for Thursday - Tale of the Tape
Mar-16-15 06:23AM  Tondiraba Ice Arena wins Concrete Building of the Year title at noodls
Mar-11-15 09:30AM  Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Mar-09-15 05:06PM  Novo Nordisk's Saxenda: New Data from Phase IIIa Study - Analyst Blog
Mar-07-15 12:40AM  Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2014 Financial Results at noodls
Mar-05-15 11:20PM  Is Arena Pharmaceuticals In Trouble? at Investopedia
Mar-04-15 07:09PM  10-K for Arena Pharmaceuticals, Inc. at Company Spotlight +6.93%
11:35AM  Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
09:34AM  Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Monday, March 2 at noodls
Mar-03-15 04:26PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure -5.61%
01:54PM  Orexigen Soars On Obesity Drug's Surprise Health Boon at Investor's Business Daily
11:51AM  Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit at TheStreet
10:28AM  Arena Pharmaceuticals' Q4 Loss Wider than Expected - Analyst Blog Zacks
Mar-02-15 06:45PM  Arena Pharmaceuticals Misses Q4 Expectations Benzinga -5.10%
05:14PM  Arena Pharmaceuticals reports 4Q loss AP
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, including potentially pulmonary arterial hypertension that is in Phase II clinical trials. The company's products under development also comprise APD334, an modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which has completed Phase I single-ascending dose trials; APD371, an agonist of the cannabinoid receptor 2 that is in Phase I clinical trials intended for the treatment of pain and fibrotic diseases; and Temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I clinical trials. In addition it manufactures drug products under a toll manufacturing agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WOODS RANDALL EDirectorMar 30Option Exercise1.3976,268105,719121,380Apr 01 06:58 PM
WOODS RANDALL EDirectorMar 30Sale4.4976,268342,25345,112Apr 01 06:58 PM
SPECTOR STEVEN WEVP, General Counsel & SecMar 17Option Exercise1.5170,000105,803198,039Mar 18 05:45 PM
SPECTOR STEVEN WEVP, General Counsel & SecMar 17Sale5.0070,000350,000128,039Mar 18 05:45 PM
LIEF JACKPresident and CEOMar 03Option Exercise1.49125,000186,250622,189Mar 04 05:54 PM
SPECTOR STEVEN WEVP, General Counsel & SecJan 08Option Exercise6.1645,000277,200173,039Jan 08 09:08 PM
SPECTOR STEVEN WEVP, General Counsel & SecJan 08Sale6.2645,000281,700128,039Jan 08 09:08 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerJan 07Option Exercise1.4950,00074,500100,000Jan 08 09:07 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerJan 07Sale5.4950,000274,50050,000Jan 08 09:07 PM
LIEF JACKChairman, President and CEOSep 17Option Exercise1.49100,000149,000441,039Sep 19 04:50 PM